Tech Journal of Colorado: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Journal of Colorado.

Press releases published on November 5, 2026

Nov. 5, 2026

Teads Holding Co. Announces Third Quarter 2026 Results

Indeterminate GlobeNewswire

Nov. 5, 2026

Enovix Organizes for Drone/Military Surge

Indeterminate GlobeNewswire

Nov. 5, 2026

Parker Delivers Record Fiscal 2027 First Quarter Results, Raises Full Year Outlook

Indeterminate GlobeNewswire

Nov. 5, 2026

Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals

Indeterminate GlobeNewswire

Nov. 5, 2026

VisionWave Targets Dual-Use Expansion Across Defense, Infrastructure, Agriculture and Aviation Markets

Indeterminate GlobeNewswire

Nov. 5, 2026

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

Indeterminate GlobeNewswire

Nov. 5, 2026

iMDx to Release Third Quarter Results on November 16, 2026

Indeterminate GlobeNewswire

Nov. 5, 2026

Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting

Indeterminate GlobeNewswire

Nov. 5, 2026

Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Indeterminate GlobeNewswire

Nov. 5, 2026

ProMIS Neurosciences to Participate in Upcoming Conferences in November

Indeterminate GlobeNewswire

Nov. 5, 2026

Kayak Therapeutics Announces IND Clearance for KT-300, a Potential First-in-Class TRIM7 Inhibitor for RAS-Driven Cancers

Indeterminate GlobeNewswire

Nov. 5, 2026

Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

Indeterminate GlobeNewswire

Nov. 5, 2026

Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases

Indeterminate GlobeNewswire

Nov. 5, 2026

Entrada Therapeutics Reports Third Quarter 2026 Financial Results

Indeterminate GlobeNewswire

Nov. 5, 2026

Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates

Indeterminate GlobeNewswire

Nov. 5, 2026

illumin Reports Third Quarter 2026 Financial Results

Indeterminate GlobeNewswire

Nov. 5, 2026

Lantheus Reports Third Quarter 2026 Financial Results

Indeterminate GlobeNewswire

Nov. 5, 2026

Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Indeterminate GlobeNewswire

Nov. 5, 2026

Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates

Indeterminate GlobeNewswire

Nov. 5, 2026

Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Indeterminate GlobeNewswire